Inotek Pharmaceuticals Corp., of Lexington, Mass., said active recruitment for Matrx-1, the first pivotal phase III trial of trabodenoson for the treatment of glaucoma, is complete. Read More

Scynexis Inc., of Jersey City, N.J., said the FDA granted orphan drug designation to its triterpenoid broad-spectrum antifungal agent, SCY-078, to treat invasive Aspergillus infections. Read More

Oncomed Pharmaceuticals Inc., of Redwood City, Calif., said it completed its underwritten public offering of 6.32 million shares of its common stock at $10 each, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock. Read More

Checkpoint Therapeutics Inc., a subsidiary of Fortress Biotech Inc., has big plans. During September the company will launch a phase I/II trial of its third-generation EGFR inhibitor CK-101 in non-small-cell lung cancer and, around the same time, a public market listing. Read More

Targeting the intrinsic clotting pathway may offer a way to reduce the risk of clotting without increasing bleeding risk, which is the tradeoff of all currently marketed antithrombotics. Read More

HONG KONG – With rapidly expanding on-the-ground operations, biotechnology giant Amgen Inc. is looking to strengthen its presence in Asian markets and to build more market share. Read More

The drum beat over high drug prices continues its steady roll, accentuated by predictable cymbal crashes calling for a rethink of government policies that create lengthy monopolies for pricy drugs. Read More